Clinical Trial Update: Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) [Phase 3]

View source ↗

Summary

Phase 3 trial results update for sofosbuvir plus ribavirin given for 12 or 16 weeks in treatment-experienced patients with chronic hepatitis C genotype 2 or 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-05-01